123 related articles for article (PubMed ID: 21878970)
1. Trial watch: ERBB2 dimerization inhibitor meets end point in breast cancer trial.
Nat Rev Drug Discov; 2011 Aug; 10(9):648. PubMed ID: 21878970
[No Abstract] [Full Text] [Related]
2. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
[No Abstract] [Full Text] [Related]
3. Trastuzumab.
Perez EA; Palmieri FM; Brock SM
Cancer Treat Res; 2009; 151():181-96. PubMed ID: 19593513
[No Abstract] [Full Text] [Related]
4. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203
[No Abstract] [Full Text] [Related]
5. HER2 inhibition: from discovery to clinical practice.
Chang JC
Clin Cancer Res; 2007 Jan; 13(1):1-3. PubMed ID: 17200331
[No Abstract] [Full Text] [Related]
6. [Monoclonal antibodies as adjuvant breast cancer therapy. Tumor cells in continuing sleep?].
MMW Fortschr Med; 2001 Nov; 143(44):56. PubMed ID: 11732401
[No Abstract] [Full Text] [Related]
7. Expression status of the autophagy-regulatory gene ATG6/BECN1 in ERBB2-positive breast carcinomas: bypassing ERBB2-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies.
Vazquez-Martin A; Cufí S; Oliveras-Ferraros C; Martin-Castillo B; Del Barco S; López-Bonet E; Menendez JA
Genes Chromosomes Cancer; 2011 Apr; 50(4):284-90. PubMed ID: 21319263
[No Abstract] [Full Text] [Related]
8. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
9. [ERBB2/HER2: from molecular to clinical oncology].
Khanson KP; Imianitov EN
Vopr Onkol; 2002; 48(2):137-45. PubMed ID: 12227060
[No Abstract] [Full Text] [Related]
10. Treating the HER2 pathway in early and advanced breast cancer.
Pegram MD
Hematol Oncol Clin North Am; 2013 Aug; 27(4):751-65, viii. PubMed ID: 23915743
[TBL] [Abstract][Full Text] [Related]
11. HER2 as a cancer stem-cell target.
Roesler R; Cornelio DB; Abujamra AL; Schwartsmann G
Lancet Oncol; 2010 Mar; 11(3):225-6. PubMed ID: 20202610
[No Abstract] [Full Text] [Related]
12. Focus on ERBB2.
Benusiglio PR
Pharmacogenomics; 2008 Jul; 9(7):825-8. PubMed ID: 18597646
[No Abstract] [Full Text] [Related]
13. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
Garnock-Jones KP; Keating GM; Scott LJ
BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285
[No Abstract] [Full Text] [Related]
14. Pertuzumab: development beyond breast cancer.
Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab trials steal show at ASCO meeting.
Tuma RS
J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
[No Abstract] [Full Text] [Related]
16. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
Roukos DH
J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
[No Abstract] [Full Text] [Related]
17. [Herceptin monotherapy in HER2(+) recurrent breast carcinoma].
Eidtmann H
Onkologie; 2002 Dec; 25 Suppl 5():14-5. PubMed ID: 23573613
[No Abstract] [Full Text] [Related]
18. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.
Kristjansdottir K; Dizon D
Expert Opin Biol Ther; 2010 Feb; 10(2):243-50. PubMed ID: 20001562
[TBL] [Abstract][Full Text] [Related]
19. ErbB/HER receptor family in breast cancer--the more we search the more we learn.
Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136
[No Abstract] [Full Text] [Related]
20. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
